We're applying the resources necessary to get these trials done as quickly as possible and best position COM360 for regulatory and commercial success. And we continue to actively review all other ways to accelerate the 006 trial. As I mentioned earlier, Mike has been traveling to clinical sites to fully understand where assistance may be needed and directing resources to them. As we encounter challenges, we're addressing them rapidly and applying those learnings to the overall pivotal program.

Oct 31, 2024 / CEO / receipt, needs a key / Kabir Nath, CEO | earnings call 2024-10-31 | transcript 324ed732-c09c-4886-bfe0-8bc49e0a34d6 | chars 16321-16819 | segment 16